Serina Therapeutics CEO Steve Ledger base salary rises to $500,000 under amended employment deal

• Serina Therapeutics entered an amended and restated employment agreement with CEO Steve Ledger on July 19, 2026.
• Sets annual base salary at USD 500,000; target annual bonus set at 50% of base salary.
• Without-cause termination or good-reason resignation outside a change in control triggers 12 months base salary, pro-rated target bonus, 12 months COBRA.
• Qualifying change-in-control termination triggers 1.5x base salary, 1.5x target bonus, pro-rated target bonus, 18 months COBRA.
• Change-in-control terms include full accelerated vesting of unvested time-based equity awards; parachute benefits subject to best-net reduction, no excise-tax gross-up.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-049426), on July 23, 2026, and is solely responsible for the information contained therein.